Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearance

Abstract

AbstractTwo novel assays have been developed, iTACT‐hepatitis B core‐related antigen (iTACT‐HBcrAg) and iTACT‐hepatitis B surface antigen (iTACT‐HBsAg) assays. We investigated the longitudinal profiles of iTACT‐HBcrAg‐ and ‐HBsAg in patients with HBsAg seroclearance (SC) (<0.05 IU/mL). This study comprises 60 HBV‐infected patients with HBsAg SC, 27 in chronic hepatitis/liver cirrhosis (CH/LC) group and 33 in inactive carrier (IC) group. Longitudinal profiles of iTACT‐HBcrAg and ‐HBsAg were examined using stored serum samples. The median period from HBsAg SC to iTACT‐HBcrAg loss or to the last observation was longer in the CH/LC group than the IC group (39 vs. −3 months, p = 0.004), but this tendency was not observed in that by iTACT‐HBsAg. Comparing the times of iTACT‐HBcrAg and ‐HBsAg loss, the rate of patients who lost HBcrAg first was significantly higher in the IC group (p = 0.008). The cumulative incidence rate of iTACT‐HBcrAg loss after HBsAg SC was higher in the IC group that the CH/LC group (p = 0.002). Patients in the CH/LC group had higher rates of detectable iTACT‐HBcrAg than those in the IC group after HBsAg SC, suggesting that the presence of HBcrAg possibly contribute to the progression of chronic hepatitis B.